Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy: later-stage trial registry
3 of 5 indexed Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Chronic Inflammatory Demyelinating Polyradiculoneuropathy: 5 US clinical trials tracked, 3 recruiting.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 2 of these trials.
Enrollment posture brief
Registry condition chronic-inflammatory-demyelinating-polyradiculoneuropathy
OPEN 3 | RECR 60% | LATE 3 | EARLY 0 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Inflammatory Demyelinating Polyradiculoneuropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Inflammatory Demyelinating Polyradiculoneuropathy is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Inflammatory Demyelinating Polyradiculoneuropathy research.
argenx accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Inflammatory Demyelinating Polyradiculoneuropathy enrolment sits around 140 participants.
Median target enrolment is 140 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Chronic Inflammatory Demyelinating Polyradiculoneuropathy research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
argenx
NCT07264426
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
NCT07091630
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Sanofi
NCT06290128
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
Mayo Clinic
NCT03584022
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Baxalta now part of Shire
NCT02955355
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Inflammatory Demyelinating Polyradiculoneuropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Inflammatory Demyelinating Polyradiculoneuropathy page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- argenx sponsors the most Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials on record, review their full trial history before evaluating a specific study. See argenx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Inflammatory Demyelinating Polyradiculoneuropathy condition card totals 5 registered trials; most-linked intervention Biopsy Only; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.